Skip to content

Trial · Interventional

CompletedNot applicableResults postedRegistry data

The Biology of Resilience

Overview

Status
Completed
Phase
Not applicable
Enrollment
270 participants (actual)
Sponsor
Harvard School of Public Health (HSPH) · Other
Design
Randomized · Triple masking
Countries
1 country

United States

Start
Feb 2009
Primary completion
Apr 2012
Completion
Apr 2012
First posted
11 Nov 2009 (estimated)
Last update posted
26 Nov 2012 (estimated)
Conditions
Oxytocin · Placebo

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20092010201120122013
  1. N/A

    The Biology of Resilience

    NCT01011465

    Feb 2009 to Apr 2012

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Positive social relationships have consistently been associated with better health, although the neurobiological underpinnings of these observed effects remain largely unknown. The overall goal of the proposed work is to explore novel biological pathways that may explain how social relationships influence health. Recent theorizing suggests that the oxytocin system may underlie some of the observed beneficial effects. Four hypotheses will be examined: 1. Oxytocin ameliorates the deleterious neuroendocrine, cardiovascular, and subjective effects of stress. 2. Oxytocin and social support have similar and additive stress-buffering effects. 3. Effects of oxytocin are evident among younger and older adults. 4. Effects of oxytocin are stronger in women vs men.

Interventions

  • intranasal oxytocinDrug
  • PlaceboDrug
  • Social supportBehavioral
  • No Social SupportBehavioral

Arms6

  • Experimental

    Oxytocin

    One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol

  • Placebo comparator

    Placebo

    The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray

  • Experimental

    Social Support

    Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks

  • Placebo comparator

    No Social Support

    Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.

  • Other

    Female Gender

    Effects of oxytocin and social support are examined among women versus men

  • Other

    Male Gender

    Consider effects of oxytocin and social support in men versus women

Primary outcomes3

Outcomes the sponsor listed as primary.

  1. Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure

    Time frame · within 2 hours of treatment

    Registry description

    Systolic blood pressure (SBP)is connected with reaction to exposure to stress. Systolic blood pressure is collected at baseline and after nasal spray administration/directly before stress tasks; it represents anticipatory stress reaction. This measure represents the difference between baseline and pre-task systolic blood pressure values. A greater difference score represents an increase from baseline in systolic blood pressure during the pre-task, and so a larger difference score represents higher reactivity. A lower difference score, or negative difference score, indicates a lower increase, or even decrease, from baseline in systolic blood pressure during the pre-task and reflects less reactivity. Reactivity is associated with increased risk of developing hypertension. Range of baseline/pre-count differences in SBP: -11 to 37.7

  2. Difference of Pre-count and Baseline Self-reported Negative Affect (Using Negative Sub-scale of Positive and Negative Affect Schedule (PANAS) Measure).

    Time frame · 2 hours

    Registry description

    Based on 20-item Positive and Negative Affect Schedule (PANAS) which comprises two mood scales, positive affect and negative affect. Each item is rated on a 5-point scale ranging from (1 = very slightly or not at all) to (5 = extremely) to indicate how the respondent felt at the moment the question was asked. Here, we've used the negative affect sub-scale which consists of the sum of the 10 negative affect items, with a possible range of 10 (least negative affect) to 50 (most negative affect). This score was measured at baseline (study range: 10 to 29) and directly before stress exposure (study range: 10 to 37), and the reported value is the difference between these two scores (range of differences: -13 to 26). It estimates negative affect due to anticipatory stress. The value is the difference between the pre-stress measure and baseline measure, therefore a larger number for the difference means a bigger increase in negative affect due to anticipatory stress, and is a worse outcome.

  3. Speech Threat and Challenge

    Time frame · 2 hours

    Registry description

    Measure of threat and challenge calculated from observation of non-verbal behavioral cues during stress exposure. Threat (negative reaction) results when an individual does not feel that he or she has sufficient resources to complete a task or manage a difficult situation. Its reverse, challenge (positive reaction), occurs when an individual perceives that he or she has sufficient resources. Independent observers used videotapes of behavior during the stress tasks and rated participants on 7 point scales for 11 challenge-related behaviors (comfortable, confident, enthusiastic, clear, alert, high level of eye contact, etc), and for 8 threat-related behaviors (agitation, rigid posture, speech disfluency, etc). Challenge scores were averaged, and threat scores averaged then reverse-scored. The mean of challenge and reversed threat scores comprise the score used here. Range: 1.1 to 6.1, with higher scores representing more challenge orientation and reflecting a better outcome.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· within 2 hours of treatment

Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure

GroupValue (mm Hg)Spread
Oxytocin Group9.48.2
Placebo Group12.97.9
Female11.39.3
Male11.17.5
Social Support - Alone10.77.4
Social Support - Friend11.79.2
Primary outcomeMean· 2 hours

Difference of Pre-count and Baseline Self-reported Negative Affect (Using Negative Sub-scale of Positive and Negative Affect Schedule (PANAS) Measure).

GroupValue (units on a scale)Spread
Oxytocin Group1.44.5
Placebo Group1.84.1
Female2.14.7
Male1.23.9
Social Support - Alone1.84.9
Social Support - Friend1.23.1
Primary outcomeMean· 2 hours

Speech Threat and Challenge

GroupValue (units on a scale)Spread
Oxytocin Group4.61.0
Placebo Group4.61.0
Female4.51.0
Male4.61.0
Social Support - Alone4.60.9
Social Support - Friend4.61.1

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Female, OT, AloneEffects of intranasal oxytocin and social support examined among women versus men. Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered. Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.–0 / 360 / 36
Female, OT, FriendEffects of intranasal oxytocin and social support examined among women versus men. Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered. Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.–0 / 200 / 20
Female, Placebo, AloneEffects of intranasal oxytocin and social support examined among women versus men. Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used. Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.–0 / 360 / 36
Female, Placebo, FriendEffects of intranasal oxytocin and social support examined among women versus men. Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used. Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.–0 / 180 / 18
Male, OT, AloneEffects of intranasal oxytocin and social support examined among men versus women. Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered. Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.–0 / 470 / 47
Male, OT, FriendEffects of intranasal oxytocin and social support examined among men versus women. Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered. Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.–0 / 290 / 29
Male, Placebo, AloneEffects of intranasal oxytocin and social support examined among men versus women. Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used. Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.–0 / 520 / 52
Male, Placebo, FriendEffects of intranasal oxytocin and social support examined among men versus women. Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used. Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.–0 / 320 / 32

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

0 studies on this page

Indexing hint: Randomized controlled trial · 2009

Protocol for an experimental investigation of the roles of oxytocin and social support in neuroendocrine, cardiovascular, and subjective responses to stress across age and gender.

Kubzansky et al. 2009BMC public healthcited by 12

PMID 20025778PMC2805640DOI 10.1186/1471-2458-9-481PUB-20025778

CC BY
Download PDF

More studies

1 study on this page

PubMed tag: none · 2012

Corrected

A heartfelt response: Oxytocin effects on response to social stress in men and women.

Kubzansky et al. 2012Biological psychologycited by 99

PMID 22387929PMC3327158DOI 10.1016/j.biopsycho.2012.02.010PUB-22387929

Rights unknown

Eligibility

Who could join, as posted.

Sex
All
Age
from 22 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * age 22-65, BMI \< 30, healthy, English-speaking, 9th grade reading level. Exclusion Criteria: * any known medical condition (including mental disorders) or on any type of medication * high levels of social anxiety * smokers * high rates of alcohol or drug use * pregnant or suspected pregnant * breastfeeding * blood pressures \> 140/90 mm Hg * subject does not have a close friend available to participate in the study with him/her

PepBank is a research reference. Talk to a doctor before you use any peptide.